Mereo BioPharma and Ultragenyx Provide Update on Phase 3 Orbit and Cosmic Studies of UX143 in Osteogenesis Imperfecta

Mereo BioPharma Group plc

The Phase 3 Orbit study final analysis is expected around end of 2025, with a threshold of p<0.04.
DMC informed Ultragenyx that UX143 has an acceptable safety profile and study should continue to final analysis.
Safety in the younger patient population (Cosmic study) is consistent with other studies; no interim analysis of Cosmic data.
Final analyses will occur after patients have been on therapy for at least 18 months; threshold for Cosmic is p<0.05.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.